Home  »  Companies   »  Are Investors Unfairly Punishing Ionis Pharmaceuti...

Are Investors Unfairly Punishing Ionis Pharmaceuticals Inc. (NASDAQ:IONS)?

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) has a beta of 1.10. The stock’s Relative Strength Index (RSI) is 36.99, with weekly volatility at 3.89% and ATR at 1.72. The IONS stock’s 52-week price range has touched low of $35.10 and a $64.37 high. Its shares traded higher over the last trading session, gaining 2.33% on 05/14/21. The shares fell to a low of $37.26 before closing at $38.24. Intraday shares traded counted 2.26 million, which was -45.74% lower than its 30-day average trading volume of 1.55M. IONS’s previous close was $37.37 while the outstanding shares total 140.77M.

Investors have identified the Biotechnology company Ionis Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $5.27 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.

Ionis Pharmaceuticals Inc. (IONS) Fundamentals that are to be considered.

When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For IONS, the company has in raw cash 414.15 million on their books with 69.5 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 1.99 billion total, with 295.11 million as their total liabilities.

Having a look at the company’s valuation, the company is expected to record -1.34 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on IONS sounds very interesting.

Is the stock of IONS attractive?

In related news, Chief Executive Officer, Monia Brett P sold 236 shares of the company’s stock in a transaction that recorded on Mar 01. The sale was performed at an average price of 54.27, for a total value of 12,809. As the sale deal closes, the Exec Chairman of the Board, CROOKE STANLEY T now sold 28,333 shares of the company’s stock, valued at 1,805,812. Also, EVP & General Counsel, O’NEIL PATRICK R. sold 5,324 shares of the company’s stock in a deal that was recorded on Jan 25. The shares were price at an average price of 63.50 per share, with a total market value of 338,074. Following this completion of acquisition, the Exec Chairman of the Board, CROOKE STANLEY T now holds 40,000 shares of the company’s stock, valued at 2,467,000. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.20%.

9 out of 21 analysts covering the stock have rated it a Buy, while 8 have maintained a Hold recommendation on Ionis Pharmaceuticals Inc.. 3 analysts has assigned a Sell rating on the IONS stock. The 12-month mean consensus price target for the company’s shares has been set at $58.80.

Leave a Comment

Your email address will not be published. Required fields are marked *